eatimate of completing phase 3, page-2

That's probably correct for the full trial, it's likely an interim assessment will be made at the completion of 95 events. Following, an FDA filing could be made under their existing agreement if the results are statistically significant. Could go either way, although I do have faith it can get approval at the full completion of the trial. It's going to be a volatile stock in the next 12 months.